These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36468787)

  • 1. Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy.
    Chan JSK; Lee YHA; Liu K; Hui JMH; Dee EC; Ng K; Satti DI; Tang P; Tse G; Ng CF
    Eur J Clin Invest; 2023 Apr; 53(4):e13932. PubMed ID: 36468787
    [No Abstract]   [Full Text] [Related]  

  • 2. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry.
    Kwon DH; Vashisht R; Borno HT; Aggarwal RR; Small EJ; Butte AJ; Huang FW
    Ann Oncol; 2021 May; 32(5):678-679. PubMed ID: 33571636
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?
    Turco F; Tucci M; Buttigliero C
    Minerva Urol Nephrol; 2021 Dec; 73(6):870-872. PubMed ID: 35144376
    [No Abstract]   [Full Text] [Related]  

  • 4. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
    Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
    J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Kollmeier MA; Zelefsky MJ
    Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE.
    Gong J; Posadas EM
    JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35877083
    [No Abstract]   [Full Text] [Related]  

  • 7. Recovery of androgens after prostate cancer therapy.
    Hargreave TB; Ghosh C
    Clin Oncol (R Coll Radiol); 2001; 13(4):289-90. PubMed ID: 11554628
    [No Abstract]   [Full Text] [Related]  

  • 8. The impact of long-term androgen deprivation therapy on cognitive function and socioeconomic decision making in prostate cancer patients.
    Holtfrerich SKC; Knipper S; Purwins J; Castens J; Beyer B; Schlomm T; Diekhof EK
    Psychooncology; 2020 Aug; 29(8):1338-1346. PubMed ID: 32539186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hormone therapy in advanced and generalized carcinoma of the prostate].
    Vachalovský V; Dvorácek J; Voboril V
    Cas Lek Cesk; 1998 Aug; 137(17):532-6. PubMed ID: 9787507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Associated with Osteoporosis Management Among Veterans Who Received Androgen Deprivation Therapy for Prostate Cancer.
    Solimeo SL; Lund BC; McCoy KD; Sarrazin MV; Hoffman R
    J Gen Intern Med; 2021 Oct; 36(10):3270-3272. PubMed ID: 33483816
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of radiation and androgen deprivation therapy for advanced prostate cancer.
    Jani AB; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):41-7. PubMed ID: 25554467
    [No Abstract]   [Full Text] [Related]  

  • 13. Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety.
    Labban M; Alkassis M; Alkhatib K; Briggs L; Cole AP; Kibel AS; Trinh QD
    Urol Clin North Am; 2022 May; 49(2):309-321. PubMed ID: 35428436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary androgen deprivation therapy in men with prostate cancer.
    Laufman L
    JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer: is androgen-deprivation therapy chosen wisely?
    Villanueva MT
    Nat Rev Clin Oncol; 2014 Sep; 11(9):501. PubMed ID: 25073003
    [No Abstract]   [Full Text] [Related]  

  • 16. [Heavy ion radiotherapy for prostate cancer -- the role of hormone therapy].
    Suzuki K; Matsui H; Kawamura H; Ohno T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):159-63. PubMed ID: 25743135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How early is early: androgen deprivation for prostate-specific antigen relapse in prostate cancer.
    Duchesne GM; Syme R; Howell D
    J Clin Oncol; 2006 Jun; 24(18):2964; author reply 2965. PubMed ID: 16782936
    [No Abstract]   [Full Text] [Related]  

  • 18. Does Radiotherapy Plus Androgen-Deprivation Therapy Represent the Best Treatment Approach in Elderly Patients With Locally Advanced Prostate Cancer?
    Gandaglia G; Fossati N; Montorsi F; Briganti A
    J Clin Oncol; 2015 Sep; 33(25):2831-2. PubMed ID: 26215938
    [No Abstract]   [Full Text] [Related]  

  • 19. Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial).
    Mulder MB; Birnie E; van Dijck-van Boetzelaer C; van de Geijn GJ; Boevé E; Westerman EM; Hamberg P
    Acta Oncol; 2021 Apr; 60(4):539-543. PubMed ID: 33356721
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostate cancer: Increased dementia risk following androgen deprivation therapy?
    Martins RN; Gandy S
    Nat Rev Urol; 2016 Apr; 13(4):188-9. PubMed ID: 26902342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.